Clinical Study
High Dose Thiotepa in Patients with Relapsed or Refractory Osteosarcomas: Experience of the SFCE Group
Table 2
Patient characteristics at the time of relapse or progression treated with high dose thiotepa.
| | Number of patients | % |
| Patient characteristics | | | Age, years | | | Median | 15.9 | | Range | 4 to 31 | | Disease status at study entry | | | Refractory disease | 2 | 4.4 | First relapse | 26 | 57.8 | Subsequent relapse | 17 | 37.8 | Site of last relapse | | | Lung only | 23 | 51 | Lung + another site | 15 | 33 | Bone only | 1 | 2.2 | Other | 4 | 9.3 | Relapse operability | | | Operable | 20 | 46.5 | Inoperable | 23 | 53.5 | Missing value | 2 | | Radiological response | | | Partial response | 12 | 30.8 | Stable disease | 18 | 46.2 | Progressive disease | 9 | 23.1 | Not evaluable | 6 | | Histological response after thiotepa | | | Good response | 9 | 29.0 | Poor response | 22 | 71.0 | No surgery | 14 | |
|
|